Protalix BioTherapeutics Inc.
www.protalix.com
Latest From Protalix BioTherapeutics Inc.
Protalix and Chiesi Plan Q1 2020 Filing For Accelerated FDA Approval
The companies plan to use surrogate endpoint data to win approval to challenge Sanofi and Shire for the Fabry disease market.
Deal Watch: LEO Pharma Expands Market Reach Through Bayer Dermatology Deal
LEO Pharma is buying branded topical treatments worth more than €280m in annual sales from Bayer. Also, Apricus and Sellos agree to merge, Lilly partners on translation inhibitors with Anima, and Merck leverages Sutro's technology in cancer and autoimmune partnership.
More Evidence Needed For Chiesi’s Ultra Orphan Lamzede, Says NICE
Chiesi still has work to do to convince NICE that its ultra rare disease treatment Lamzede is a cost-effective treatment.
Chiesi Committed To Becoming A Major Player In Rare Diseases
The Italian group has got the green light in Europe for Lamzede, the first disease-modifying therapy for alpha mannosidosis and believes the drug, along with Procysbi and an investigational Fabry disease being developed with Protalix, constitute a strong portfolio in the rare metabolic disease area.
Company Information
- Industry
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
- Transgenics
- Pharmaceuticals
- Therapeutic Areas
- Metabolic Disorders
- Alias(es)
- Protalix BioTherapeutics Ltd.
- Metabogal Ltd.
- Orthodontix Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
Middle East
-
Israel
-
Israel
-
Middle East
- Parent & Subsidiaries
- Protalix BioTherapeutics Inc.
- Senior Management
-
Dror Bashan, Pres. & CEO
Eyal Rubin, SVP, CFO
Yoseph Shaaltiel, PhD, EVP, R&D
Ronen Rosenberg, VP, Commercial & Product Planning
William Taylor, VP, Bus. Dev. - Contact Info
-
Protalix BioTherapeutics Inc.
Phone: (972) 4-902-8100
2 Snunit St., Science Park
P.O. Box 455 Karmiel, 21000
Israel
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice